|
Careers |
Bioanalytical Study DirectorDrug Metabolism/PharmacokineticsSUMMARY: The Study Director is responsible for the execution of bioanalytical protocols that meet stated timelines and quality standards in a GLP environment. These bioanalytical studies are performed at Accium in support of a Sponsor’s Phase 1 clinical study, including pharmacokinetics, absolute bioavailability, metabolite profiling, mass balance and microdosing studies. Clinical studies are conducted using compounds that are lightly labeled with 14C isotope. These Phase 1 studies are typically performed in 6-18 healthy volunteers over several days at a single clinical site. The clinic submits the samples to Accium BioSciences for processing and quantitation on Accium’s 0.5 mV Accelerator Mass Spectrometer (AMS), an ultra-sensitive mass spectrometer capable of quantifying drugs present at attomole (10^-18 M) concentration. The Study Director is the primary point of contact with the Sponsor, initially helping to conceptualize the study, writing the Bioanalytical Protocol, scheduling internal resources, training and managing laboratory staff and then overseeing the proper conduct of the study as described in the protocol. The Study Director works in the front end of the process where sample preparation, HPLC and processing are performed prior to transfer to Graphitization and AMS Laboratories. The position reports to the President and Scientific Director. ESSENTIAL DUTIES AND RESPONSIBILITIES:
Requirements:
About Accium BioSciences: Accium BioSciences is a privately-held contract research company offering ultrasensitive bioanalytical services in support of early-phase clinical trials. The company’s clients are primarily large pharmaceutical companies investigating the bioavailability, pharmacokinetics and metabolism (PK/ADME) of new chemical entities. Our services are based on accelerator mass spectrometry (AMS), a detection platform for quantifying drugs and metabolites in clinical samples with unprecedented sensitivity. In April 2006, Accium BioSciences launched the first US-based AMS Facility in the U.S dedicated to pharmaceutical services. The company is based in Seattle, Washington. For more information, please visit www.acciumbio.com, or call Ali Arjomand (206) 281-3915, e-mail arjomand@acciumbio.com.
|
Copyright © Accium BioSciences, Inc. 2004-2010 |